A Phase 2 interventional study of asciminib and best available treatment in Leukemia, Chronic Myelogenous, sponsored by Novartis Pharmaceuticals. Completed at 20 sites in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-04-18.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 8 open to participants now, 13 under way, 2 of them phase 3. asciminib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 13th largest by enrollment, is one of 5 that started in 2021, is one of 11 in phase 2, and was the 7th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →8 of the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Thomas Ernst, Prof. Dr. med. · Sites in Germany
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Australia, Brazil and 14 more countries
Ages 1–18
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Spain
Ages 18+
Novartis Pharmaceuticals · Sites in France
Ages 18–99
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
asciminib: first FDA approval 2021 (SCEMBLIX), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 5 · Phase 4 2
First in 2014; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 100 across the 21 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 9 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 32nd largest by enrollment of the 63 interventional ones that give a count, is one of 8 that started in 2021, is one of 19 in phase 2, and was the 65th registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
2 of the studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03906292University of JenaFrontline Asciminib Combination in Chronic Phase CML | 2027-03 |
| NCT04925479Novartis PharmaceuticalsStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | 2027-09-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
The purpose of this Chinese bridging study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of asciminib versus best available therapy in Chinese patients with Chronic Myelogenous Leukemia in chronic phase, previously treated with 2 or more tyrosine kinase inhibitors to support related indication registration in China.
The primary objective of the study is to evaluate the Major Molecular Response (MMR) rate of asciminib treatment at 24 weeks.
The purpose of this Chinese bridging study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of asciminib versus best available therapy (BAT) in Chinese patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs) to support related indication registration in China.
This study will enroll the participants 1) who failed their most recent TKI therapy by meeting the definition of treatment failure as per the 2013 European Leukemia Net (ELN) guidelines, or 2) who were intolerant to the most recent TKI therapy and must have BCR-ABL1 ratio > 0.1% IS at screening.
Eligible participants will be randomized into asciminib arm or the BAT arm on a 2:1 ratio, to receive asciminib treatment (continuous 40 mg BID) or BAT from Day 1 until the end of study treatment period defined as 96 weeks after the last participant receives the first dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed as CML-CP:
Participants must meet all of the following laboratory values at the screening visit:
\< 15% blasts in peripheral blood and bone marrow \< 30% blasts plus promyelocytes in peripheral blood and bone marrow \< 20% basophils in the peripheral blood
Exclusion Criteria:
Cardiac or cardiac repolarization abnormality, including any of the following:
History within 6 months prior to starting study treatment of myocardial infarction, angina pectoris, coronary artery bypass graft cardiac arrhythmias , complete left bundle branch block, high-grade AV block at screening ≥450 msec (male participants), ≥460 msec (female participants)
Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
Risk factors for Torsades de Pointes including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia Concomitant medication(s) with a "Known risk of Torsades de Pointes" that cannot be discontinued or replaced 7 days prior to starting study drug by safe alternative medication.
Inability to determine the QTcF interval
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive asciminib (40 mg BID continuous)
Drug: asciminib
Patients will receive best available therapy chosen by investigator
Other: best available treatment
Asciminib comes in 20 mg and 40 mg tablets and is taken orally twice daily
Also known as: ABL001
Best available treatment will be based on investigator's choice identified prior to randomization. Dose and frequency will depend on label and institutional guidelines for various BAT
Major molecular response rate of asciminib
Evaluate the major molecular response rate at 24 weeks in asciminib arm
Time frame: week 24
Cytogenetic response (CyR) rate
Evaluate the cytogenetic response rate (Complete, Partial, Major, Minor, Minimal, no response) at and by all scheduled data collection time points including 24, 48 and 96 weeks for both asciminib arm and best available treatment arm.
Time frame: 24, 48, 96 weeks
Major molecular response rate of best available treatment arm
Evaluate the major molecular response rate at week 24 of best available treatment arm, and compare with asciminib arm
Time frame: week 24
Major molecular response rate of both asciminib arm and BAT armn time points
Evaluate the major molecular response rate, collected at all scheduled data collection time point (except week 24)
Time frame: Up to all participants received at least 96 weeks of randomized study treatment, except week 24
major molecular response rate by all scheduled data collection time points
Evaluate the major molecular rate by all scheduled data collection time points including 24, 48 and 96 weeks by treatment group
Time frame: Up to all participants received at least 96 weeks of randomized study treatment
Time to major molecular response rate
Evaluate the time from the date of the first dose of study drug to the date of the first documented MMR by treatment group
Time frame: Up to all participants received at least 96 weeks of randomized study treatment
Duration of major molecular response
First document major molecular response to loss of MMR up to 96 weeks after last participant receive the first dose
Time frame: Up to all participants received at least 96 weeks of randomized study treatment
Overall survival
To evaluate the time from the date of randomization to the date of death (including the survival follow-up period)
Time frame: Up to all participants received at least 96 weeks of randomized study treatment, plus 30 days for safety follow up
Progression free survival
Evaluate the time from the date of randomization to the earliest occurrence of documented disease progression to AP/BC or the date of death from any cause (including progressions and deaths observed during the survival follow-up period)
Time frame: Up to all participants received at least 96 weeks of randomized study treatment, plus 30 days for safety follow up
Pharmacokinetics (PK) parameter of asciminib: Cmax
Characterize PK of asciminib in the Chinese CML-CP population. Cmax is the maximum (peak) observed plasma drug concentration after dose administration (ng/mL).
Time frame: Week 2 Day 1 (W2D1)
PK parameter of asciminib: Tmax
Characterize PK of asciminib in the Chinese CML-CP population. Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration (hr).
Time frame: Week 2 Day 1 (W2D1)
PK parameter of asciminib: Ctrough
Characterize PK of asciminib in the Chinese CML-CP population. Trough plasma concentrations (Ctrough)
Time frame: Week 2 Day 1 (W2D1)
PK parameter of asciminib: AUCtau
Characterize PK of asciminib in the Chinese CML-CP population. The partial area under the plasma concentration-time curve from dose time to tau (ng\*hr/mL). For a bid regimen, Tau=12h.
Time frame: Week 2 Day 1 (W2D1)
PK parameter of asciminib: AUClast
Characterize PK of asciminib in the Chinese CML-CP population. AUClast is the The AUC from the time of dosing to the time of the last measurable plasma concentration (Tlast) (ng\*hr/mL)
Time frame: Week 2 Day 1 (W2D1)
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from Dec 2021 to primary completion in May 2023, 17 months.
Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's 17 months is below that.
Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Asciminib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →